ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that Jason Lettmann, the Company's Chief Executive Officer will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference being held in New York City from December 3-5, 2024.
加利福尼亞州南舊金山，2024年11月26日（全球新聞網）-- ALX Oncology Holdings Inc.（"ALX Oncology"或"公司"）（納斯達克：ALXO），是一家臨床階段的生物技術公司，致力於推進通過增強免疫系統以新方式治療癌症並延長患者生命的療法，今天宣佈公司首席執行官Jason Lettmann將參加於2024年12月3日至5日在紐約市舉行的派傑投資第36屆年度醫療會議的爐邊聊天。
Format: Fireside chat with analyst, Christopher Raymond and 1x1 meetings
Date: Tuesday, December 3, 2024
Time: 9:30 AM EST
Location: New York City, NY
Webcast link: Available here
格式：與分析師Christopher Raymond的爐邊聊天及1對1會議
日期：2024年12月3日星期二
時間：東部標準時間上午9:30
地點：紐約市，紐約
網絡直播鏈接：可在此處獲取
The live webcast for the Piper Sandler fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at .com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.
可以通過訪問ALX Oncology網站的投資者部分，進入事件選項卡下的資訊和事件選項來訪問派傑投資的爐邊談話的直播網絡廣播，網址爲.com。直播網絡廣播的回放將在爐邊談話日期後的90天內進行存檔。
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives. ALX Oncology's lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at and on LinkedIn @ALX Oncology.
關於ALX Oncology
alx oncology（納斯達克：ALXO）是一家臨床階段的生物技術公司，推進增強免疫系統治療癌症的療法，以新的方式延長患者的生命。 alx oncology的主導治療候選藥物evorpacept已經展示出潛力，可以成爲未來免疫腫瘤治療的基石。 Evorpacept目前正在多項進行中的臨床試驗中評估，涵蓋廣泛的癌症適應症。 更多信息請查閱鏈接和LinkedIn @ALX Oncology。
CONTACT: Company Contact:
Caitlyn Doherty, Manager, Corporate Communications, ALX Oncology
cdoherty@alxoncology.com
(650) 466-7125
Investor Contact:
Malini Chatterjee, Ph.D., Blueprint Life Science Group
mchatterjee@bplifescience.com
(917) 330-4269
Media Contact:
Audra Friis, Sam Brown, Inc.
audrafriis@sambrown.com
(917) 519-9577
聯繫方式：公司聯繫人：
凱特琳·多赫提，ALX Oncology公司通信經理
cdoherty@alxoncology.com
(650) 466-7125
投資者聯繫人：
馬利尼·查特吉，博士，藍圖生命科學集團
mchatterjee@bplifescience.com
(917) 330-4269
媒體聯繫：
奧德拉·弗里斯，薩姆·布朗公司
audrafriis@sambrown.com
(917) 519-9577
譯文內容由第三人軟體翻譯。
